Ziółkowska-Suchanek Iwona, Rozwadowska Natalia
Institute of Human Genetics, Polish Academy of Sciences, Strzeszyńska 32, 60-479 Poznań, Poland.
Genes (Basel). 2025 May 12;16(5):569. doi: 10.3390/genes16050569.
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide, characterized by late diagnosis and resistance to conventional therapies. Gene therapy has emerged as a promising alternative for NSCLC therapy, especially for patients with advanced disease who have exhausted conventional treatments. This article delved into the current developments in gene therapy for NSCLC, including gene replacement and tumor suppressor gene therapy, gene silencing, CRISPR/Cas9 gene editing, and immune modulation with CAR-T cell therapy. In addition, the challenges and future prospects of gene-based therapies for NSCLC were discussed.
非小细胞肺癌(NSCLC)是全球癌症相关死亡的主要原因,其特征为诊断较晚且对传统疗法具有抗性。基因治疗已成为NSCLC治疗的一种有前景的替代方法,尤其适用于那些已用尽传统治疗方法的晚期疾病患者。本文深入探讨了NSCLC基因治疗的当前进展,包括基因替代和肿瘤抑制基因治疗、基因沉默、CRISPR/Cas9基因编辑以及CAR-T细胞疗法的免疫调节。此外,还讨论了NSCLC基因疗法面临的挑战和未来前景。